Cargando…

Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma

PURPOSE: We designed a comprehensive multiple myeloma targeted sequencing panel to identify common genomic abnormalities in a single assay and validated it against known standards. EXPERIMENTAL DESIGN: The panel comprised 228 genes/exons for mutations, 6 regions for translocations, and 56 regions fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sudha, Parvathi, Ahsan, Aarif, Ashby, Cody, Kausar, Tasneem, Khera, Akhil, Kazeroun, Mohammad H., Hsu, Chih-Chao, Wang, Lin, Fitzsimons, Evelyn, Salminen, Outi, Blaney, Patrick, Czader, Magdalena, Williams, Jonathan, Abu Zaid, Mohammad I., Ansari-Pour, Naser, Yong, Kwee L., van Rhee, Frits, Pierceall, William E., Morgan, Gareth J., Flynt, Erin, Gooding, Sarah, Abonour, Rafat, Ramasamy, Karthik, Thakurta, Anjan, Walker, Brian A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Precision Medicine and Imaging
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250632/ https://www.ncbi.nlm.nih.gov/pubmed/35522533 http://dx.doi.org/10.1158/1078-0432.CCR-21-3695

Ejemplares similares

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
por: Gooding, Sarah, et al.
Publicado: (2022)

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
por: Thakurta, Anjan, et al.
Publicado: (2021)

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways
por: Karagoz, Kubra, et al.
Publicado: (2022)

Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma
por: Ziccheddu, Bachisio, et al.
Publicado: (2021)

Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple myeloma
por: Johnson, Travis S., et al.
Publicado: (2023)

Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma
por: Liu, Enze, et al.
Publicado: (2023)

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
por: Ansari-Pour, Naser, et al.
Publicado: (2023)

Cryopreservation Preserves Cell-Type Composition and Gene Expression Profiles in Bone Marrow Aspirates From Multiple Myeloma Patients
por: Chen, Duojiao, et al.
Publicado: (2021)

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
por: Flynt, Erin, et al.
Publicado: (2020)

Differential RNA splicing as a potentially important driver mechanism in multiple myeloma
por: Bauer, Michael A., et al.
Publicado: (2020)

A Personalized Mass Spectrometry–Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM)
por: Liyasova, Mariya, et al.
Publicado: (2021)

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
por: Bjorklund, Chad C., et al.
Publicado: (2019)

Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
por: Ashby, Cody, et al.
Publicado: (2022)

4565 Sex-Specific Differences in the Genomic Landscape of Pediatric and Adult Glioblastoma
por: Ivanov, Nikolay A., et al.
Publicado: (2020)

A Simple Panel of IDH1 and P53 in Differential Diagnosis Between Low-Grade Astrocytoma and Reactive Gliosis
por: Geramizadeh, Bita, et al.
Publicado: (2021)

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
por: Dimopoulos, M A, et al.
Publicado: (2014)

Genomic Selection for Wheat Blast in a Diversity Panel, Breeding Panel and Full-Sibs Panel
por: Juliana, Philomin, et al.
Publicado: (2022)

Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
por: Van Ness, Brian, et al.
Publicado: (2008)

Recognition of early mortality in multiple myeloma by a prediction matrix
por: Terebelo, Howard, et al.
Publicado: (2017)

PANEL DISCUSSION: MYELOMA & LYMPHOMA: Tuesday 12 October 2004, 14:00–16:00
Publicado: (2005)

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
por: Walker, Brian A., et al.
Publicado: (2018)

338 The Alabama Genomic Health Initiative: Integrating Genomic Medicine into Primary Care
por: Limdi, Nita A, et al.
Publicado: (2023)

Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses
por: de Haart, S J, et al.
Publicado: (2016)

Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients
por: Ting, Kay Reen, et al.
Publicado: (2017)

Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus
por: Mario, Boccadoro, et al.
Publicado: (2021)

Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways
por: Ortiz-Estévez, María, et al.
Publicado: (2021)

Determinants recognized by murine rheumatoid factors: molecular localization using a panel of mouse myeloma variant immunoglobulins
Publicado: (1983)

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients
por: Kortuem, K M, et al.
Publicado: (2016)

P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL
por: Amatangelo, M., et al.
Publicado: (2022)

Somatic Genomic Mosaicism in Multiple Myeloma
por: Ye, Christine J., et al.
Publicado: (2020)

A Genomic Reference Panel for Drosophila serrata
por: Reddiex, Adam J., et al.
Publicado: (2018)

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group
por: Samur, Mehmet Kemal, et al.
Publicado: (2020)

Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer
por: Waks, Adrienne G., et al.
Publicado: (2022)

Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma
por: Zhang, Li, et al.
Publicado: (2016)

Genomic prediction for growth using a low-density SNP panel in dromedary camels
por: Bitaraf Sani, Morteza, et al.
Publicado: (2021)

287 Genomic and Immunologic Characterization of Lung Adenocarcinoma in Never Smokers vs. Smokers
por: Li, P. Jonathan, et al.
Publicado: (2023)

Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers
por: Laskin, Janessa, et al.
Publicado: (2015)

Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
por: Vasudev, Naveen S., et al.
Publicado: (2023)

Panel Doctors and Panel Chemists
Publicado: (1914)

Multiple myeloma and physical activity
por: Lecat, Catherine S. Y., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jgn0k0felrdhllq7g9g4v60mvo